share_log

iBio Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lynx1 Capital Management LP(9.99%),Weston Nichols(9.99%)

iBio Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals

iBio Inc | SC 13G：超過5%持股股東披露文件
SEC announcement ·  04/02 07:28
牛牛AI助理已提取核心訊息
On March 26, 2024, iBio Inc, a biotechnology company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission. The filing was made by Lynx1 Capital Management LP, a Delaware-based investment manager, and Weston Nichols, the sole member of Lynx1 Capital Management GP LLC, which is the general partner of the investment manager. The filing indicates that Lynx1 Capital Management LP and Mr. Nichols collectively hold 878,492 shares of iBio Inc's common stock, which includes 278,492 shares issuable upon the exercise of warrants. This represents 9.99% of the company's class of securities, taking into account a beneficial ownership blocker that prevents them from exercising warrants that would result in ownership exceeding 9.99% of the outstanding common stock. The filing asserts that the shares were not acquired with the purpose or effect of changing or influencing the control of iBio Inc.
On March 26, 2024, iBio Inc, a biotechnology company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission. The filing was made by Lynx1 Capital Management LP, a Delaware-based investment manager, and Weston Nichols, the sole member of Lynx1 Capital Management GP LLC, which is the general partner of the investment manager. The filing indicates that Lynx1 Capital Management LP and Mr. Nichols collectively hold 878,492 shares of iBio Inc's common stock, which includes 278,492 shares issuable upon the exercise of warrants. This represents 9.99% of the company's class of securities, taking into account a beneficial ownership blocker that prevents them from exercising warrants that would result in ownership exceeding 9.99% of the outstanding common stock. The filing asserts that the shares were not acquired with the purpose or effect of changing or influencing the control of iBio Inc.
2024年3月26日，生物技術公司iBio Inc成爲向美國證券交易委員會提交的附表13G文件的主體。該文件由總部位於特拉華州的投資管理公司Lynx1 Capital Management LP和該投資管理公司的普通合夥人Lynx1 Capital Management GP LLC的唯一成員韋斯頓·尼科爾斯提交。文件顯示，Lynx1 Capital Management LP和Nichols先生共持有iBio Inc的878,492股普通股，其中包括行使認股權證時可發行的278,492股股票。這佔公司證券類別的9.99％，考慮到受益所有權封鎖因素，該封鎖使他們無法行使認股權證，導致所有權超過已發行普通股的9.99％。該文件稱，收購這些股票的目的或效果不是爲了改變或影響iBio Inc的控制權。
2024年3月26日，生物技術公司iBio Inc成爲向美國證券交易委員會提交的附表13G文件的主體。該文件由總部位於特拉華州的投資管理公司Lynx1 Capital Management LP和該投資管理公司的普通合夥人Lynx1 Capital Management GP LLC的唯一成員韋斯頓·尼科爾斯提交。文件顯示，Lynx1 Capital Management LP和Nichols先生共持有iBio Inc的878,492股普通股，其中包括行使認股權證時可發行的278,492股股票。這佔公司證券類別的9.99％，考慮到受益所有權封鎖因素，該封鎖使他們無法行使認股權證，導致所有權超過已發行普通股的9.99％。該文件稱，收購這些股票的目的或效果不是爲了改變或影響iBio Inc的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。